ABBV News and Press, AbbVie Inc. From 02/24/26

2026-02-24 13:50:12 ET The last time I wrote an article on MoonLake Immunotherapeutics ( MLTX ), it was in a Seeking Alpha article entitled " MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest. " At that time, things were looking very good for th...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, Baystreet.ca News Commentary , The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion by 2033 at a compound annual growth rate of 7.2% [1] . Forecasts for the broader oncolog...

2026-02-20 08:47:46 ET More on markets Dividend power plays: 10 large caps delivering 5% yields and 10%+ returns Tech’s internal split: Semiconductor strength masks software breakdown Dividend picks: 20 large-cap defensive stocks outperforming the market in ...

2026-02-20 07:30:47 ET In January, I rated Corcept Therapeutics ( CORT ) a Hold , citing severe binary risk of its looming patent appeal against Teva Teva Pharmaceutical Industries ( TEVA ). On February 19th, the US Court of Appeals for the Federal Circuit ...

2026-02-20 06:01:50 ET More on AbbVie AbbVie: Dominating Immunology While Building Oncology Upside AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript AbbVie: The Market Is Getting It Wrong China drug licensin...

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) PR Newswire First all-oral, fixed-duration combination regimen approved for previously...

2026-02-19 13:31:04 ET More on AbbVie, AstraZeneca PLC, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable AbbVie: Dominating Immunology While Building Oncology Upside Merck posts n...

2026-02-19 12:35:00 ET Healthcare is a multi-trillion-dollar industry in the United States alone. With 2024 spending exceeding $5.3 trillion, the sector is nearly one-fifth of the U.S. economy. That alone justifies holding several healthcare stocks in your long-term portfolio, though it can...

2026-02-19 11:28:56 ET Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , " Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time.... R...

2026-02-19 09:39:32 ET More on AbbVie AbbVie: Dominating Immunology While Building Oncology Upside AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript AbbVie: The Market Is Getting It Wrong AbbVie files lawsui...